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A comparative analysis of assessment procedures for authorization of all European Union (EU)
applications for advanced therapy medicinal products (ATMPs) shows that negative opinions were
associated with a lack of clinical efficacy and identified severe safety risks. Unmet medical need was
often considered in positive opinions and outweighed scientific uncertainties. Numerous quality issues
illustrate the difficulties in this domain for ATMP development. Altogether, it suggests that setting
appropriate standards for ATMP authorization in Europe, similar to elsewhere, is a learning experience.
The experimental characteristics of authorized ATMPs urge regulators, industry, and clinical practice to
pay accurate attention to post-marketing risk management to limit patient risk. Methodologies for
ATMP development and regulatory evaluations need to be continuously evaluated for the field to
flourish.
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Over the past decade, there has been increased
interest in the development of ATMPs towards
marketing authorization. In 2009, Regulation EC
No.1394/2007 came into force as the first spe-
cific regulatory framework for approval of this
potentially new class of medicinal products in
the EU [1,2]. By August 2017, the number of
ATMP regulatory procedures for marketing au-
thorization was 16, a number that has been
coined as relatively low given the recent im-
pressive advances in basic molecular and clinical
science in the field of ATMPs [3–5].
It is well known that ATMP developers face
various scientific and technological challenges,
from manufacturing and quality issues [6] to1328 www.drugdiscoverytoday.com
1359-6446/ã 2018 The Authors. Pupreclinical and clinical efficacy and safety issues
[1]. Moreover, additional hurdles in the trajec-
tory towards approval are experienced by aca-
demic developers, such as a lack of regulatory
knowledge, insufficient financial support, and
clinical trial-related problems, such as recruit-
ment [7]. Although Regulation EC No. 1394/2007
includes high-level requirements for approval,
because the field is rapidly evolving, standard-
ization of regulatory requirements for approval
is difficult and perhaps undesirable. Conse-
quently, during the decision-making process,
regulators need to deal with novel issues that
have not been previously discussed in other
regulatory procedures [8]. Given these devel-
opmental and regulatory complexities, scientificblished by Elsevier Ltd. This is an open access article under the CC BY-uncertainties during benefit–risk assessments
are prevalent.
In this study, we provide insight into decision-
making for approval of ATMPs in Europe be-
tween 1 January 2009 and 1 July 2017 by
characterizing regulatory assessment proce-
dures for marketing authorization, and analyz-
ing identified major issues and considerations
for benefit–risk outcomes (see Appendix 1 in the
supplemental information online [9–13]).
Cohort analysis of assessment procedures
From the 14 ATMPs included in our study, five
were standard approvals, three were approved
via an expedited pathway (defined as condi-
tional approval or approval under exceptionalNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.drudis.2018.03.008
Drug Discovery Today Volume 23, Number 7  July 2018 PERSPECTIVE
TABLE 1
Products used in the analysisa
Product ATMP subtype Starting material Approval type Date of final outcome
Chondrocelect1 TEP Autologous Standard approval October 2009
Imlygic1 GTMP – in vivo N/A Standard approval October 2015
MACI1 TEP Autologous Standard approval April 2013
Provenge1 CTMP Autologous Standard approval June 2013
Strimvelis1 GTMP – ex vivo Autologous Standard approval April 2016
Holoclar1 TEP Autologous Conditional approval December 2014
Zalmoxis1 CTMP Allogeneic Conditional approval June 2016
Glybera1 GTMP – in vivo N/A Under exceptional circumstances October 2012
Advexin GTMP – in vivo N/A Nonapproval (withdrawn) December 2008
CLG GTMP – in vivo N/A Nonapproval (withdrawn) June 2009
Cerepro GTMP – in vivo N/A Nonapproval (withdrawn) April 2007
Heparesc CTMP Allogeneic Nonapproval October 2015
Hyalograft TEP Autologous Nonapproval (withdrawn) January 2013
OraNera TEP Autologous Nonapproval (withdrawn) March 2013













circumstances for this study), and six were
nonapproved (Table 1). The product profiles of
all assessed ATMPs are shown in Table 2. Char-
acteristics, such as ATMP subtype, starting ma-
terial, administration route, and storage
conditions, were diverse for the different sub-
mitted products. Orphan drug designation was
assigned to all expedited approved products,
whereas only one (out of five) standard ap-
proved products and half (three out of six) of the
nonapproved products were designated orphan
drugs. For the expedited approved products, no
alternative treatment was available, whereas this
applied only to one out of five standard ap-
proved products and two (out of six) nonap-
proved products.
All standard approvals were tested according
to standards on sterility, purity, and viability upon
release. However, for the expedited approvals and
nonapprovals, these release tests were not always
discussed in the European public assessment
report (EPAR). Remarkable was the unspecified
shelf-life and storage conditions for nonapproved
products (four out of six).
The design of pivotal clinical trials was more
robust for standard versus expedited approved
and nonapproved products. For most (four out
of five) of the standard approvals, a randomized
controlled Phase 3 clinical trial was performed.
By contrast, this was the case for only two (out of
six) nonapproved and for none of the expedited
approved products. The number of patients
recruited was higher for the standard approved
products (mean: 244 patients, range: 12–341)
compared with nonapproved products (mean:
120 patients, range: 26–241) and expedited
approved products (mean: 57 patients, range:
14–106). The defined primary endpoints were
considered clinically relevant for all standard
approved products, for some expedited ap-proved ATMPs (two out of three) and for half
(three out of six) of the nonapproved products.
A significant effect on the primary endpoint
was demonstrated for all standard approved
products. By contrast, significant effects were
not demonstrated in two (out of three) expe-
dited approved products and in five (out of six)
nonapproved products. No added clinical ben-
efit was demonstrated for most of the standard
approved (four out of five) and for all the non-
approved products. Added clinical benefit was
demonstrated for all expedited approved pro-
ducts because of the lack of alternative thera-
pies.
Analysis of major issues
Major issues were evaluated across assessment
procedures, regardless of final regulatory opin-
ion (Table 3; for detailed descriptions see Table
S1 in Appendix 2 in the supplemental infor-
mation online).
For quality, major issues were noted for all
products; for example, the vector (expedited
approval one out of three, nonapproved: two
out of six) and specific release tests (standard
approved: one out of five, expedited approved:
three out of three, nonapproved: five out of six).
Whereas developers of the approved products
were able to resolve the objections before final
regulatory decision-making, developers of the
nonapproved products were unable to resolve
these major issues, which were mostly raised
early during the assessment procedure, and
decided to withdraw their product.
Most of the major issues related to preclinical
studies were raised for nonapproved products,
concerning animal models (one out of six),
toxicology (four out of six) and efficacy studies
(one out of six). By contrast, no major issues
were noted for the approved products, exceptfor one (out of three) expedited approved
product, which concerned toxicology and was
unresolved upon final decision-making. In ad-
dition, major issues indicated for nonapproved
products were still unresolved at the time of
final decision-making.
For clinical trial design, most major issues
were also raised for nonapproved products.
These issues concerned methodological issues
or invalid clinical trial design (five out of six) and
change of endpoints or uncertain clinical rele-
vance of an endpoint (two out of six). A change
of endpoints was also noted as a major issue for
one standard and one expedited approved
product. For the approved products, the major
concerns were considered resolved, whereas all
major issues around clinical trial design for the
nonapproved products were unresolved upon
final decision-making.
Major issues related to clinical outcomes were
raised for all nonapproved products and for
Glybera1, one of the approved products. A lack
of favorable clinical outcomes for nonapproved
products related to both efficacy (six out of six)
and safety (five out of six). Furthermore, good
clinical practice (GCP) was an issue in three (out
of six) dossiers and pharmacodynamics data
were too limited in two (out of six) nonapproved
products.
Analysis of benefit–risk assessment
For standard approved ATMPs, benefit–risk
balances were mainly based on clinical efficacy
results (Table 4). The beneficial efficacy out-
comes and a favorable safety profile resulted in
a positive opinion for MACI1. The beneficial
efficacy trend for Chondrocelect1 and
Imlygic1 combined with satisfactory safety
profiles resulted in standard approval, despite
ample regulatory discussion about the clinicalwww.drugdiscoverytoday.com 1329
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TABLE 2
Elements with variables scored per marketing approval typea,b
Element Variable SA (N = 5) CA (N = 2) UEC (N = 1) NA (N = 6)
Product profile
Product type GTMP 2 0 1 3
CTMP 1 1 0 1
TEP 1 1 0 2
Combined 1 0 0 0
Starting material Autologous 4 1 0 2
Allogeneic 0 1 0 1
Not applicable 1 0 1 3
End product Refrigerated 2 0 0 0
Room temperature 2 1 0 0
Nitrogen-cryopreserved 0 1 0 1
Other-cryopreserved 1 0 1 1
Unspecified 0 0 0 4
Previous approved in other jurisdictions Yes 3 0 0 0
Indication area Cancer 2 0 0 2
Congenital, hereditary, neonatal diseases 1 0 1 2
Eye diseases 0 1 0 1
Immune system diseases 0 1 0 0
Musculoskeletal diseases 2 0 0 1
Lack alternative treatment Yes 1 2 1 2
Orphan drug designation Yes 1 2 1 3
Scientific evidence
Quality Potency assay 5 2 1 6
Release: sterility 5 1 0 4
Release: purity 5 1 0 4
Release: viability 5 2 0 2
Release: activity 3 1 1 3
Preclinical Toxicity 4 2 1 6
Efficacy 5 1 1 6
Dose 3 1 1 6
Pivotal trial design RCT 4 0 0 2
Clinical primary EP 5 1 0 4
Clinical relevance primary EP 5 2 0 3
Significant outcome 5 1 0 1
Clinical outcome Significant primary EP 5 1 0 1
Beneficial effect 1 2 1 0
Regulatory process
Scientific advice 5 2 1 4
Restricted labeling 5 1 1 0
a Per element, variables are scored for each (non-)approval type of ATMP.
b Abbreviations: CA, conditional approved; CTMP, cell therapy medicinal product; EP, endpoint; GTMP, gene therapy medicinal product; NA, non-approved; RCT, randomized controlled









trial design. Significant and clinically relevant
efficacy of Provenge1 combined with the ac-
knowledged unmet medical need for the target
indication (oncology), outweighed the risks and
uncertainties related to the safety profile.
Compelling efficacy outcomes for Strimvelis1,1330 www.drugdiscoverytoday.comwith the acknowledged unmet medical need,
outweighed risks and uncertainties surround-
ing latent severe adverse events [14]. Despite
these favorable regulatory opinions, divergent
positions were submitted for two approved
products (Imlygic1: N = 1; Provenge1: N = 13).As a prerequisite for conditional approval
pathways, the body of evidence was overall less
robust and associated with more uncertainty
compared with standard approved ATMPs
(Table 4). Uncertainty about significant clinical
benefits for Holoclar1 was recognized because
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TABLE 3
Major issues mentioned in the assessment reports for marketing authorizationa,b
Drug category Authorization Quality Preclinical Clinical trial design Clinical outcome
Approved (N = 8) Standard (N = 5) In process control (1) Endpoint (1)
Release specification (1)
Specific release test (1)
Conditional (N = 2) Specific release test (2)
UEC (N = 1) Vector (1) Toxicology (1) Endpoint (1) Efficacy (1)
Specific release test (1) Safety (1)
Non-approved (N = 6) Vector (2) Toxicology (4) Design (5) PD (2)
GMP facility (3) Animal model (1) Endpoint (2) GCP (3)
In process control (2) Efficacy (1) Efficacy (6)
GMO test (1) Safety (5)
Starting material (1)
Specific release test (1)
Specific release test (4)
a Per category (quality, preclinical, clinical trial design, and clinical outcome) the major issues including the number of products for which that major objection was raised is mentioned:
Green, resolved at time of final decision; orange, acceptable at time of final decision; red, unresolved at time of final decision.
b Abbreviations: GCP, good clinical practice; GMO, genetically modified organism; PD, pharmacodynamics.of the retrospective, nonrandomized, uncon-
trolled observational study design. Yet, this was
outweighed by the manageable risks and ac-
knowledged unmet medical need. Unmet
medical need outweighed nonconfirmatory
clinical benefit and safety because of uncer-
tainty in clinical trial design for Zalmoxis1. ATABLE 4











Approval under exceptional circumstances
Glybera1  
Nonapproval
Advexin     
CLG     
Cerepro + +
Heparesc
Hyalograft     
OraNera     
a , unsatisfactory, unresolved major objections; , uncert
trend towards satisfactory; ++, satisfactory; empty box, not 
b Abbreviation: CLG, Contusugene Ladenovec Gendux.divergent position was undersigned by three
members of the Committee for medicinal
products for human use (CHMP).
Glybera1 was approved under exceptional
circumstances (EUC) after a long and exten-
sive assessment procedure, involving many
re-evaluations by the Committee of advancedl Design Efficacy Safety 
  + ++ 
 + + 
++ ++ ++ 
+/ ++ 
+/ ++ 
+/ + + 
+/ +/ 
+/ +/ +/ 
      
    
      
    +/
  +/   
      
ainty, concerns, and risks, trend towards unsatisfactory; +/–, n
mentioned; ~, unmet medical need considered in benefit/ristherapies (CAT) and CHMP [15]. Many
uncertainties about quality, efficacy, and
safety led to unfavorable recommendations
for approval twice. Before the final re-exam-
ination, a lack of robust efficacy outcomes
was considered a major concern. Yet, a post-







































Glybera1 for a subgroup of patients (N = 5).
The unmet medical need for this subgroup
was crucial to reach approval from UEC,
taking the ultra-orphan status into consider-
ation. Consequently, the label was restricted
to this patient group. The final CHMP opinion
was not supported by 16 members, who
undersigned a divergent position.
Nonapproval of ATMPs was associated with
numerous scientific deficiencies (Table 4). Half of
the nonapproved products had an unsatisfactory
profile for all scientific evidence elements. For all
nonapproved products, the clinical trial design
was regarded as unsatisfactory, which hindered
regulators from evaluating the clinical data. Pos-
itive results related to quality and preclinical
studies were demonstrated for Cerepro. However,
an unsatisfactory clinical trial design and clinical
outcomes resulted in nonapproval. For Heparesc,
the clinical safety profile was acceptable, but the
clinical trial design and clinical efficacy were
judged to be unsatisfactory. For Hyalograft only
clinical efficacy was acceptable, but other aspects
were unsatisfactory. For four (out of six) nonap-
proved products, unmet medical need was ac-
knowledged, but did not outweigh scientific
deficiencies. During the application procedure,
five out of six nonapproved products were
withdrawn by the company before a final decision
was made by the regulators.
Pharmaceutical quality
The numerous scientific issues related to phar-
maceutical quality demonstrate that this do-
main remains problematic in the ATMP field [6].
A main pharmaceutical quality issue in the
submitted applications concerned the level of
validation of release testing quality control (QC)
for different clinical trial stages and for approval.
EU GMP requirements appear to be more
stringent compared with other jurisdictions (e.
g., USA or Japan) and might impose develop-
ment hurdles. In this context, both the revised
first-in-human clinical trials EU Guideline and the
EU GMP guideline for ATMPs give hints of quality
aspects, such as potency testing and use of
biomarkers, although the proof of that expec-
tation will ‘be in the eating’ [16–18].
Potency also frequently raised major objections
for both approved and nonapproved ATMPs. ATMP
developers experience difficulties in proper po-
tency testing because of the lack of suitable animal
models, with little or even no knowledge about the
mechanism of action, and, therefore, also lack
validated biomarkers. Developers could prevent
failure during late-stage development through
early investment inpotencyevaluation[19].Vector-
related problems belong to the fundamental de-1332 www.drugdiscoverytoday.comvelopment aspects of such products and should
have been resolved before submission for ap-
proval. This also accounts for nondefined end-
productstorageconditions andshelf-life,whichare
all associated with negative opinions for approval.
In contrast to the early days of ATMP regulation,
it is now possible to conditionally release a
product by using a rapid-release test. Our findings
demonstrate that a lack of a final release test was
often resolved by the development of a rapid-
release test for approved ATMPs. In this study, we
analyzed the quality aspects that were mentioned
and, thus, discussed in the EPARs. Although we
compare the different approvals, we do not think
that the quality requirements depend on the
approval pathway. However, the objections that
were discussed in the EPARs could have influ-
enced the approval type. Furthermore, incom-
parability of the commercial product and clinical
trial product raised major objections. This should
and could be avoided by considering future
aspects of development and proper clinical trial
design during the early stages of ATMP devel-
opment [7,20] to prevent withdrawals at Day 120
for those developers who might not have the
resources to tackle resolvable major issues.
Clinical development
The observed suboptimal clinical trial designs
that create uncertainty around clinical outcomes
are in line with earlier reports of development
hurdles experienced in the field [5,21]. However,
half of currently approved ATMPs target orphan
diseases, for which robust clinical trial design is
not always possible as a result of small patient
populations or a lack of alternative treatment
[5,22,23]. Therefore, our observations of sub-
optimal study designs under expedited approval
of ATMPs, such as lower numbers of recruited
patients, should be interpreted within the
context of orphan drugs. Yet, observations of
suboptimal study design, such as nonrandom-
ized trial design without a comparator, are in line
with findings for conditionally approved non-
orphan drugs in the EU [13].
Some major concerns related to clinical trial
design, such as a change of primary endpoint,
were also raised for standard approved ATMPs.
Yet, regulators evaluated scientific evidence as
sufficient for standard approval. In addition, un-
met medical need was acknowledged and taken
into account for decision-making. By contrast, a
robust clinical trial design and clinical outcomes
are mandatory for standard approval of conven-
tional products [12]. This suggests that EU reg-
ulators are exploring an appropriate regulatory
standard for ATMPs, where conventional products
could be used as a useful reference.Considerations for benefit–risk analysis
Here, orphan designation among the approved
ATMPs skewed the level of scientific evidence to a
nonconfirmatory nature. There is ample concern
that, in the field of not only orphan drugs, but also
targeted oncology products, the nature of evi-
dence becomes less confirmatory with the use of
nonrandomized data and surrogate endpoints
[24]. The relatively high number of orphan desig-
nations in the field of ATMPs will impact the reg-
ulatory considerations for marketing approval in
the future [25]. Unmet medical need has an im-
portant role in decision-making for the approval of
orphan ATMPs, provided that the data should at
least show some beneficial trends of efficacy or a
favorable safety profile to receive approval. This
feature is also seen in the field of regulating orphan
drugs [11]. Yet, considerations of unmet medical
need did not lead to a higher rate of positive
opinions on orphan drug approval compared with
treatments without unmet medical need [12]. This
apparent dissimilarity between orphan ATMPs and
orphan new entities needs to be explored further.
Surprisingly, conditional approval and approval
UEC for orphan ATMPs are not primarily initiated by
the developers, but by the regulators. In line with
previous work, these findings suggest that condi-
tional approval is frequently used as a rescue
option for approval [13]. For (ultra-)orphan indi-
cations, developers should take conditional ap-
proval and approval UEC into their strategic
considerations for marketing authorization instead
of leaving this to the regulators to propose.
Critically, observations of a lack of clinical
efficacy for nonapproval of ATMPs are in line
with argumentation for negative benefit–risk
opinions on conventional medicinal products.
Earlier research on conventional medicinal
products showed that beneficial, clinically rele-
vant efficacy outcomes are determinants for
approval [11]. Furthermore, our findings indicate
that the process of decision-making leading to
nonapproval is similar between ATMPs and
conventional medicinal products. Earlier re-
search showed that major issues that were un-
resolved at the time of the final decision often
led to withdrawal by the applicant [21]. Strik-
ingly, the unresolved major issues of nonap-
proved ATMPs underline the challenges to the
development of ATMPs [6,19,26]. Glybera1 is the
only approved product that appears to be an
exception to the rule to be approved despite its
uncertain benefit–risk profile; it was approved
after a long regulatory process with a restricted
label and many uncertainties [27]. Currently, the
marketing authorization holder has decided not
to extend the marketing authorization of the
product.














The current centralized system for ATMPs, in-
cluding CATexperts and a range of advantages for
ATMP developers, creates opportunity to learn
and gain experience with these innovative pro-
ducts as well as the underlying science and
technology [28]. As the field develops, it is im-
portant that regulatory standards (incrementally)
coevolve to tailor procedures and decision-mak-
ing for these ATMPs. Our observations indicate
that EU regulators are inclined to be adaptive [29]
and to endorse ATMPs for approval, without
compromising necessary evidentiary support for
positive benefit/risk opinions. There are also nu-
merous regulatory adaptations that are to be
implemented soon (e.g. the new Clinical Trial
Regulation) in the EU. These will also affect ATMP
development [30]. Others have been recently
implemented, such as the new regulatory path-
way for priority medicines (PRIME). Many of the
investigational medicines that were included in
the PRIME scheme are ATMPs [31]. Development
efforts are also rapidly evolving. The ATMPs dis-
cussed here reflect a start of a huge clinical
development pipeline [3–5,30], for which appli-
cations for approval will be filed in due course.
Thus, the current analysis reflects decision-mak-
ing for a small sample of first-generation ATMPs,
making it difficult to draw generalizable conclu-
sions for the future. It is possible that some
observations are driven by product specificity
and/or disease characteristics instead of by reg-
ulatory approval pathways. Therefore, it is crucial
to continue to monitor regulatory outcomes and
evaluate the ATMP regulatory framework.
Concluding remarks
EU regulators are making important steps in the
field of ATMPs by balancing evidentiary support
and medical needs with critical scientific uncer-
tainties that could hamper marketing approval.
The development, regulation, and clinical use of
most ATMPs are still coevolving. In this context,
defining appropriate regulatory standards taking
into account the complexities inherit to these
products is critical. Our observations concur not
only with current defined standards for ATMPs,
but also with the available space that regulations
allow for facilitated pathways. As long as the risks
are acceptable, this appears to be the way for-
ward. Yet, because of the novelty and lack of
clinical experience in this field, regulators, and
those in industry and clinical practice need to pay
accurate attention to postmarketing surveillance
and risk-minimization measures, in particular for
those products with a high degree of scientific
uncertainty upon point of approval. For the field
to flourish, developers and regulators need tocollaborate to continuously monitor and evolve
methodologies and regulations for ATMPs.
Appendix A. Supplementary data
Supplementary data associated with this article
can be found, in the online version, at https://
doi.org/10.1016/j.drudis.2018.03.008.
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